Sanofi plays catch-up in immuno-oncology with new Regeneron deal

With their first collaboration producing the potential blockbuster Praluent and other near-market medicines, Sanofi and Regeneron are likely hoping they can repeat the trick with a new $2bn-deal covering immune-oncology.

With their first collaboration producing the potential blockbuster Praluent and other near-market medicines, Sanofi and Regeneron are likely hoping they can repeat the trick with a new $2bn-deal covering immune-oncology.

The agreement is the largest closed by the French multinational since Olivier Brandicourt became CEO in April this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By 

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

More from Therapy Areas

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.